1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Roche On Track To Supplement Relaunched Susvimo’s Label

 
• By Joseph Haas

Having relaunched Susvimo for wet AMD, Roche now has the ocular implant under FDA review for approval in two diabetic ophthalmic indications and presented two-year data in those settings.

DME
Roche hopes to add two diabetes-related eye diseases to the Susvimo label • Source: Shutterstock

Now back on the market as a refillable ocular implant for wet age-related macular degeneration (AMD), Roche Holding AG/Genentech, Inc. ’s Susvimo (ranibizumab injection) may be poised to add indications in diabetic macular edema (DME) and diabetic retinopathy (DR) as Roche seeks to build up the product as a complement to its blockbuster wet AMD, DME and retinal vein occlusion therapy Vabysmo (faricimab).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.